雙鷺藥業(002038.SZ)擬斥4.9億元參設新里程醫療健康 收購2家以上三級醫院
格隆匯1月7日丨雙鷺藥業(002038.SZ)公佈,2020年1月7日,公司與北京國科新里程醫院管理有限公司(“北京國科”)簽署《出資協議書》,由雙方共同出資設立北京國科新里程醫療健康科技有限公司,擬收購2家以上三級醫院。標的公司註冊資本為10億元,其中,公司認繳出資4.9億元人民幣,佔註冊資本的49%;北京國科認繳出資5.1億元,佔註冊資本的51%。
公司名稱:北京國科新里程醫療健康科技有限公司;經營範圍:技術開發、技術諮詢、技術轉讓、技術推廣、技術服務;軟件開發;基礎軟件服務;應用軟件服務;計算機系統服務;醫學研究與試驗發展;醫院管理(不含診療活動);商務信息諮詢;企業管理諮詢。投資方向:主要集中於大型醫療機構或醫療集團的投資收購及經營管理,公司成立後擬收購2家以上三級醫院。公司的經營策略為抓住國家鼓勵社會資本辦醫機遇,聚焦區域醫療中心建設,對投資醫院進行深耕細作,以醫療機構為終端形成大健康產業閉環。
此次投資設立參股公司,有利於增強公司在醫療產業的投資佈局,適應醫藥、醫療領域的整體發展趨勢,優化和拓寬公司產品的商業供應鏈。同時加強與中國科學院及中國科學院大學合作及藥物臨牀試驗有效推進,加快公司大健康產業鏈的佈局,有利於提升公司產品在終端市場的份額,從而提升公司的綜合競爭實力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.